|
1
|
Pan F, Bao YH, Huang RY, Li J and Zhang Z:
Epidemiological study on the incidence of large intestine cancer in
Wenzhou city from 2001 to 2005. Zhonghua Zhongliu Fangzhi Zazhi.
14:1286–1287. 2007.(In Chinese).
|
|
2
|
Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P,
Li GL, Wu LY and He J: Report of incidence and mortality in China
cancer registries, 2008. Chin J Cancer Res. 24:171–180. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
László L: Predictive and prognostric
factors in the complex treatment of patients with colorectal
cancer. Magy Onkol. 54:383–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Xu J, Zhang RX, Zhang Y, Ou QJ,
Li JQ, Jiang ZZ, Wu XJ, Fang YJ and Zheng L: CD169 identifies an
activated CD8(+) T cell subset in regional lymph nodes that
predicts favorable prognosis in colorectal cancer patients.
Oncoimmunology. 5:e11776902016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jensen EV, Block GE, Smith S, Kyser K and
DeSombre ER: Estrogen receptors and breast cancer response to
adrenalectomy. Natl Cancer Inst Monogr. 34:55–70. 1971.PubMed/NCBI
|
|
7
|
Jordan VC, Gapstur S and Morrow M:
Selective estrogen receptor modulation and reduction in risk of
breast cancer, osteoporosis, and coronary heart disease. J Natl
Cancer Inst. 93:1449–1457. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Couse JF, Lindzey J, Grandien K,
Gustafsson JA and Korach KS: Tissue distribution and quantitative
analysis of estrogen receptor-alpha (ERalpha) and estrogen
receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type
and ERalpha-knockout mouse. Endocrinology. 138:4613–4621. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paech K, Webb P, Kuiper GG, Nilsson S,
Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand
activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
Science. 277:1508–1510. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Enmark E, Pelto-Huikko M, Grandien K,
Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M and
Gustafsson JA: Human estrogen receptor beta-gene structure,
chromosomal localization, and expression pattern. J Clin Endocrinol
Metab. 82:4258–4265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell-Thompson M, Lynch IJ and Bhardwaj
B: Expression of estrogen receptor (ER) subtypes and ERbeta
isoforms in colon cancer. Cancer Res. 61:632–640. 2001.PubMed/NCBI
|
|
12
|
Takeyama J, Suzuki T, Inoue S, Kaneko C,
Nagura H, Harada N and Sasano H: Expression and cellular
localization of estrogen receptors alpha and beta in the human
fetus. J Clin Endocrinol Metab. 86:2258–2262. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh S and Langman MJ: Oestrogen and
colonic epithelial cell growth. Gut. 37:737–739. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grodstein F, Newcomb PA and Stampfer MJ:
Postmenopausal hormone therapy and the risk of colorectal cancer: A
review and meta-analysis. Am J Med. 106:574–582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fiorelli G, Picariello L, Martineti V,
Tonelli F and Brandi ML: Functional estrogen receptor beta in colon
cancer cells. Biochem Biophys Res Commun. 261:521–527. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arai N, Ström A, Rafter JJ and Gustafsson
JA: Estrogen receptor beta mRNA in colon cancer cells: Growth
effects of estrogen and genistein. Biochem Biophys Res Commun.
270:425–431. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith CL, Nawaz Z and O'Malley BW:
Coactivator and corepressor regulation of the agonist/antagonist
activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol
Endocrinol. 11:657–666. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shao R, Feng Y, Zou S, Weijdegård B, Wu G,
Brännström M and Billig H: The role of estrogen in the
pathophysiology of tubal ectopic pregnancy. Am J Transl Res.
4:269–278. 2012.PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chute CG, Willett WC, Colditz GA, Stampfer
MJ, Rosner B and Speizer FE: A prospective study of reproductive
history and exogenous estrogens on the risk of colorectal cancer in
women. Epidemiology. 2:201–207. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calle EE, Miracle-McMahill HL, Thun MJ and
Heath CW Jr: Estrogen replacement therapy and risk of fatal colon
cancer in a prospective cohort of postmenopausal women. J Natl
Cancer Inst. 87:517–523. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
English MA, Kane KF, Cruickshank N,
Langman MJ, Stewart PM and Hewison M: Loss of estrogen inactivation
in colonic cancer. J Clin Endocrinol Metab. 84:2080–2085. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oduwole OO, Isomaa VV, Nokelainen PA,
Stenbäck F and Vihko PT: Downregulation of estrogen-metabolizing 17
beta-hydroxysteroid dehydrogenase type 2 expression correlates
inversely with Ki67 proliferation marker in colon-cancer
development. Int J Cancer. 97:1–6. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neuhouser ML, Aragaki AK, Prentice RL,
Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan
BJ, Tinker LF, et al: Overweight, obesity, and postmenopausal
invasive breast cancer risk: A secondary analysis of the women's
health initiative randomized clinical trials. JAMA Oncol.
1:611–621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chlebowski RT, Wactawski-Wende J,
Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA,
Taylor VM, Harris R, Chen C, et al: Estrogen plus progestin and
colorectal cancer in postmenopausal women. N Engl J Med.
350:991–1004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rossouw JE, Anderson GL, Prentice RL,
LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA,
Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: Principal results from
the women's health initiative randomized controlled trial. JAMA.
288:321–333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paruthiyil S, Parmar H, Kerekatte V, Cunha
GR, Firestone GL and Leitman DC: Estrogen receptor beta inhibits
human breast cancer cell proliferation and tumor formation by
causing a G2 cell cycle arrest. Cancer Res. 64:423–428. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YH, Wang C, Meng K, Chen LB and Zhou
XJ: Influence of survivin and caspase-3 on cell apoptosis and
prognosis in gastric carcinoma. World J Gastroenterol.
10:1984–1988. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hendrickse CW, Jones CE, Donovan IA,
Neoptolemos JP and Baker PR: Oestrogen and progesterone receptors
in colorectal cancer and human colonic cancer cell lines. Br J
Surg. 80:636–640. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fox EM, Davis RJ and Shupnik MA: ERbeta in
breast cancer-onlooker, passive player, or active protector?
Steroids. 73:1039–1051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miller WR, Anderson TJ, Dixon JM and
Saunders PT: Oestrogen receptor beta and neoadjuvant therapy with
tamoxifen: Prediction of response and effects of treatment. Br J
Cancer. 94:1333–1338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rivera-Guevara C and Camacho J: Tamoxifen
and its new derivatives in cancer research. Recent Pat Anticancer
Drug Discov. 6:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garrido JM, Manuela E, Garrido PJ,
Oliveira-Brett AM and Borges F: An electrochemical outlook on
tamoxifen biotransformation: Current and future prospects. Curr
Drug Metab. 12:372–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Krishnan K, Campbell S, Abdel-Rahman F,
Whaley S and Stone WL: Cancer chemoprevention drug targets. Curr
Drug Targets. 4:45–54. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu
G, Lu LJ, Shen ZZ, Ding J and Shao ZM: ERbeta exerts multiple
stimulative effects on human breast carcinoma cells. Oncogene.
23:5799–5806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Onozato W, Yamashita K, Yamashita K, Kuba
T, Katoh H, Nakamura T, Sato T, Ihara A, Okayasu I and Watanabe M:
Genetic alterations of K-ras may reflect prognosis in stage III
colon cancer patients below 60 years of age. J Surg Oncol.
103:25–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sharrard RM, Royds JA, Rogers S and
Shorthouse AJ: Patterns of methylation of the c-myc gene in human
colorectal cancer progression. Br J Cancer. 65:667–672. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun N, Meng Q and Tian A: Expressions of
the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their
relationship. Am J Surg. 200:341–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roger L, Jullien L, Gire V and Roux P:
Gain of oncogenic function of p53 mutants regulates E-cadherin
expression uncoupled from cell invasion in colon cancer cells. J
Cell Sci. 123:1295–1305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang XH, Fu ZX, Zhao Y, Shen W, Wu X and
Wang C: Survivin: An overexpression protein with notable cellular
localization and multiple roles in colon cancer. Chinese-German J
Clin Oncol. 9:519–523. 2010. View Article : Google Scholar
|
|
42
|
Garg H, Suri P, Gupta JC, Talwar GP and
Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell
Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Scantlebury JB, Luo J, Thorstad WL,
El-Mofty SK and Lewis JS Jr: Cyclin D1-a prognostic marker in
oropharyngeal squamous cell carcinoma that is tightly associated
with high-risk human papillomavirus status. Hum Pathol.
44:1672–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
El-Hafez AA, El Aaty Shawky A and Hasan B:
Cyclin D1 overexpression associates with favourable prognostic
factors in invasive breast carcinoma. Cancer Biomark. 12:149–154.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang GJ, Kimijima I, Onda M, Kanno M,
Sato H, Watanabe T, Tsuchiya A, Abe R and Takenoshita S:
Tamoxifen-induced apoptosis in breast cancer cells relates to
down-regulation of bcl-2, but not bax and bcl-X(L), without
alteration of p53 protein levels. Clin Cancer Res. 5:2971–2977.
1999.PubMed/NCBI
|
|
46
|
Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG
and Ma T: Expression of survivin protein in human colorectal
carcinogenesis. World J Gastroenterol. 9:974–977. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW,
Yun JP, Zhang MF and Wan DS: Elevated expressions of MMP7, TROP2,
and survivin are associated with survival, disease recurrence, and
liver metastasis of colon cancer. Int J Colorectal Dis. 24:875–884.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
He Q, Liang CH and Lippard SJ: Steroid
hormones induce HMG1 overexpression and sensitize breast cancer
cells to cisplatin and carboplatin. Proc Natl Acad Sci USA.
97:5768–5772. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hwang TS, Han HS, Hong YC, Lee HJ and Paik
NS: Prognostic value of combined analysis of cyclin D1 and estrogen
receptor status in breast cancer patients. Pathol Int. 53:74–80.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kdroxenidou L, Ohlson LC and
Porsch-Hällström I: Long-term 17 a1pha-ethinyl estradiol treatment
decreses cyclin E and cdlc2 expression, reduces cdk2 kinase
activity and inhibits S phase entry in regenerating rat liver. J
Hepatol. 43:478–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
